- Home
- PESI vs SLS Comparison
PESI vs SLS Comparison
Compare PESI & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PESI | SLS |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.9M | 208.0M |
| IPO Year | 1992 | N/A |
Fundamental Metrics
Financial Performance| Metric | PESI | SLS |
|---|---|---|
| Price | $14.35 | $3.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 129.4K | ★ 8.3M |
| Earning Date | 03-12-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $60,661,000.00 | N/A |
| Revenue This Year | $9.91 | N/A |
| Revenue Next Year | $62.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.25 | $0.95 |
| 52 Week High | $16.50 | $5.18 |
Technical Indicators
Market Signals| Indicator | PESI | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 45.61 |
| Support Level | $14.55 | $3.66 |
| Resistance Level | $16.05 | $4.20 |
| Average True Range (ATR) | 0.88 | 0.42 |
| MACD | -0.05 | -0.14 |
| Stochastic Oscillator | 30.32 | 1.48 |
Price Performance
Historical ComparisonAbout PESI Perma-Fix Environmental Services Inc.
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: The treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.